The ASCO Post

💻 #ASCOAI: #AI accepted in screening guidelines @NCCN now recommends earlier #breastcancer screening (age 35) for high-risk women identified by AI or risk assessment tools. ‼️ A significant move toward personalized screening. Read more here ➡️ ascoai.org/articles/2026/…

Precision risk modeling in CMML: 📊 55% had risk reclassification 🧬 Molecular data improved prognostication 🎯 Transplant decision changes in 31% 👉 New prognostic scoring system may redefine management 🔹 Lanino et al | @JCO_ASCO | #leusm Read more: ascopost.com/news/april-202…

🔬 Evolving renal cell carcinoma treatment strategies In this roundtable discussion, experts consider treatment strategies after adjuvant pembrolizumab, highlighting timing of recurrence, IO rechallenge, TKI combinations, etc. #KidneyCancer #RCC 🎥 Watch: ascopost.com//video-roundta…

📊 #Childhoodcancer survival is rising CONCORD-4 shows 5-year survival is improving worldwide with many countries nearing/exceeding @WHO’s 60% target by 2030. ➡️ 60% target may not be high enough 🔹 Claudia Allemani, PhD | @TheLancet Explore the findings: ascopost.com/news/april-202…

🖥️ #ASCOAI: #AI is transforming clinical trial matching. A neurosymbolic multiagent system matched patients to trials 4x faster than manual review, outperforming LLM benchmarks. ➡️ Scaling access to trials may finally be within reach 🔹 @MassiveBio 🔗 ascoai.org/articles/2026/…

🩺 Nancy L. Lewis, MD, MBS, FACP, had been named Chief Scientific Officer of @NCCN, bringing deep expertise in clinical trials and oncology research. 🔬 A key role in shaping guidelines, research, & innovation. Read the full article ➡️ ascopost.com/news/april-202… #cancer #leadership

🔬 Integrating #AI into the #oncology workflow LLMs may capture key genomic and histologic findings in #pathology summaries more consistently than physician summaries. ➡️ Reduce errors, documentation burden 🔹 Mohamed E. Abazeed, MD, PhD | @JCOCCI_ASCO ascopost.com/news/april-202…

💍 Marriage as a #cancer risk factor? In a large U.S. study: never-married adults had significantly higher cancer incidence vs ever-married adults. 👉 A reminder that risk extends beyond biology ✍️ Paulo S. Pinheiro, PhD of @umiamimedicine Learn more: ascopost.com/news/april-202…

In a large genomic analysis from the 100,000 Genomes Project: 📊 5% had pathogenic germline variants 🧬 Common genes: CHEK2, BRCA2, ATM ⚖️ Many variants not linked to tumor type 🔹 James Whitworth, PhD of @Cambridge_Uni | @TheLanccetOncl 🔗 ascopost.com/news/april-202…

🏆 Honoring a pioneer in cancer research James P. Allison, PhD, receives the 2026 @AACR Lifetime Achievement Award for discoveries that led to CTLA-4 checkpoint inhibition, transforming #cancercare. Read here: ascopost.com/news/april-202…

🖥️ #ASCOAI: AI vs dermatologists in #melanoma detection A new meta-analysis shows comparable performance, and even better results when clinicians use #AI support. 👉 More real-world validation is needed. Explore the finding: ascoai.org/articles/2026/…

🤰Pregnancy after breast cancer? Reassuring new data POSITIVE trial: Temporary interruption of endocrine therapy for pregnancy appears feasible, safe in selected patients with HR+ #breastcancer. 👩‍⚕️ @AnnPartridgeMD of @DanaFarber at #MBCC26 | #OncoFertility ascopost.com/news/april-202…

🔬 What works for treatment may not work for prevention In the Alliance A221805 trial: Duloxetine showed no benefit in preventing neuropathy in patients with #colorectalcancer on oxaliplatin. 🔸Ellen M. Lavoie Smith, PhD, MSN | @JCOOA_ASCO Read the report: ascopost.com/news/april-202…

🖥️ #ASCOAI: #AI-generated “synthetic data” may help accelerate #cancerresearch These datasets mimic real-world outcomes with low re-identification risk. ➡️ Supports trial design, data sharing, and precision decision-making. 🔹 @eddy_saad of @DanaFarber ascoai.org/articles/2026/…

Long-term risks in patients with chronic lymphocytic leukemia: 📊 #Skincancer risk: 13.5% vs 6.9% ⏱ Earlier onset ⚠️ Higher metastasis & mortality ✅ A strong case for proactive screening and patient counseling. 🔹Blomberg Drejøe et al | @JAMADerm 🔗 ascopost.com/news/april-202…

🔬Rethinking progression in #prostatecancer Post hoc analysis shows discordance between imaging & PSA in patients on enzalutamide. 📈 Radiographic progression may occur without PSA increase 👨‍⚕️ Andrew J. Armstrong, MD, ScM, FACP of @DukeHealth | @JCO_ASCO ascopost.com/news/april-202…

🧬 A new frontier in cancer prevention for Lynch syndrome Researchers identified a blood-based biomarker using T-cell receptors to stratify #cancer risk, before symptoms develop 🔹 Led by Eduardo Vilar-Sanchez, MD, PhD (@evilarsan) of @UTMDAnderson 🔗 ascopost.com/news/april-202…

⚖️ Proton vs photon therapy in phase III TORPEdO trial IMPT and IMRT showed comparable outcomes in locally advanced #oropharyngealcancer; no significant differences seen in QoL or survival. 🔸 @DrDThomson of @TheChristieNHS | @TheLancet 🔗 ascopost.com/news/april-202…

🖥️ #ASCOAI: New research highlights μPharma, an #AI-powered microdevice that predicts sensitivity to targeted therapies in pediatric T-ALL within hours. ➡️ Offers a path toward real-time, personalized treatment decisions. Read the full article: ascoai.org/articles/2026/…

Ablative radiotherapy + chemo for large intrahepatic #cholangiocarcinoma led to: 📊 OS: 28.7 vs 11.9 months w/chemo alone 📉 Lower liver failure rates ✔ No grade 4–5 AEs ➡️ May expand treatment options 🔬 Led by @ebludmir + @eugenekoay of @UTMDAnderson ascopost.com/news/april-202…